Predictive Signature of Benralizumab Response. BENRAPRED Study.

Severe asthma is a long-term lung condition where standard inhalers are not enough to keep symptoms under control. People living with severe asthma often experience sudden breathlessness, wheezing, and frightening flare-ups that may require hospital care. Benralizumab (brand name Fasenra) is a targeted treatment given by regular injection under the skin. It works by lowering the number of specific white blood cells that cause swelling and irritation in the airways.

Although benralizumab helps many people, it does not work equally well for everyone. At the moment, doctors have to wait several months to see if a patient gets better. The BENRAPRED study aims to change this. Researchers are studying gene patterns in the blood to see if they can find clear clues showing whether someone will be a strong responder, an average responder, or someone who needs a different treatment entirely.

If researchers can identify these blood markers, doctors will be able to match people with severe asthma to the best treatment straight away. This personalised approach could prevent unnecessary delays, reduce the risk of serious asthma attacks, and help patients feel better much faster.